Project description:Transcriptional profiling of human HepG2 cells comparing control DMSO-treated cells with K7174-treated cell Two-condition experiment, DMSO-HepG2 vs. K7174-HepG2 cells. Biological replicates: 1 control, 1 treated, independently grown and harvested. One replicate per array.
Project description:<p>In this study, five human cell lines (A2780, Chang liver, HEK293T, HeLa, and HepG2) were used as models and exposed to mixtures of neonicotinoids (NEOs) and their metabolites. The mixture concentrations were prepared based on human biomonitoring data to reflect the actual detected levels of NEOs and their metabolites in human urine. Each cell line was treated with the corresponding human biomonitoring-matched mixture at specified concentrations, alongside a 0.1% DMSO solvent control group. After 48 hours of exposure, intracellular metabolites were extracted and subjected to untargeted metabolomic analysis using an Orbitrap Exploris 120 mass spectrometer in both positive and negative ion modes. During the acquisition process, pooled quality control samples (prepared by mixing equal volumes of all samples) were interspersed to monitor system stability.</p>
Project description:LncRNA and mRNA profiling of human iPSC derived cerebral organoids (Propofol treated vs. DMSO control) were determined. LncRNA and mRNA profiling of human iPSC derived cerebral organoids (Propofol treated vs. DMSO control) were determined.
Project description:Purpose: The goals of this study is to analyze the transcriptome change during retinal explant culture treated with pharmacological chaperone of rhodopsin (YC-001). Methods: The WT and RhoP23H/+ mouse eyes were enucleated at post natal day 15 and retinal explant were cultured for 24 hours followed by the 24 hours treatment with pharmacological chaperone of rhodopsin (YC-001) and dmso vehicle control. Another group of P23H/+ retinal explant was treated further till 9 days. We compare the transcript of RhoP23H/+ dmso with WT dmso at 24 hour treatment (1 days in vitro (1DIV)). RhoP23H/+ YC-001 were also compared with RhoP23H/+ dmso treated retinal explant at 1DIV and 9DIV. Results: A total of 338 differentially expressed genes (DEGs) were identified comparing the RhoP23H/+ vs. WT retinal explants with DMSO and 56 DEGs were identified comparing RhoP23H/+ YC-001 treated vs. DMSO treated retinal explant at 1 DIV. Further we observed an increased number of DEGs (8,597) comparing RhoP23H/+ vs dmso vehicle control at 9DIV. DEGs were identified using stringency with >1.5-fold change and P-value<0.05. Interestingly, we found 40 common genes when comparing RhoP23H/+ YC-001 treated vs. DMSO at 1DIV and 9DIV. Conclusions: This study used RNA-seq technology which represents the transcriptome of WT and RhoP23H/+ mouse retinal explant with and without pharmacological chaperone of rhodopsin (YC-001). Our NGS results show that YC-001 affect many biological pathways including visual transduction, protein homeostasis pathways and decreases the expression of immune response activation genes, to rescue the rhodospin homeostasis and retinal morphology in the retinal explant of P23H Rho mouse model of retinitis pigmentosa (RP).
Project description:To obtain the gene expression profiles of triple-negative breast cancer MDA-MB-231 cells and liver cancer HepG2 cells perturbed by the BET inhibitor JQ1, we treated MDA-MB-231 and HepG2 cells with either DMSO (control) or 10 μM JQ1 for 24 hours. By comparing the expression profiles of DMSO-treated cells with those treated with JQ1, we can identify the genes affected by JQ1.
